AABB's donor hemovigilance efforts focus primarily on education, collaboration with other international organizations, and projects undertaken by the AABB Donor Hemovigilance Working Group.
COVID-19 Convalescent Plasma Donor Hemovigilance Study
Convalescent plasma from individuals recently recovered from SARS-CoV-2 infection can passively transfer donor antibodies and is being used as a potential therapy for currently infected COVID-19 patients. Recent studies demonstrate that transfusion of convalescent plasma is safe in hospitalized COVID-19 patients. However, the safety of collecting plasma from donors recently recovered from SARS-CoV-2 infection has not been evaluated. Given that most COVID-19 convalescent plasma (CCP) donors are highly motivated to donate, are often first time apheresis donors and are all recently recovered from a novel viral infection with unknown long-term sequelae, it is imperative to evaluate the safety of CCP donation and to determine whether CCP donors are at increased risk of donor adverse events (DAE) compared to conventional plasma donors.
Objective of this Survey Study: To determine the incidence of DAE for CCP donors and to assess whether it is greater than the reported incidence of DAE for conventional plasma donors.
A sub-group of AABB Donor Hemovigilance Working Group is currently collecting data through September 1, 2020 for this study. Please contact Srijana Rajbhandary at email@example.com for any questions.
Severity Grading Tool for Donor Adverse Events
The Severity Grading Tool for Donor Adverse Events developed and validated by a sub-group of the AABB Donor Hemovigilance Working Group, is now finalized and results of the formal validation have been
published (Transfusion, 2020).
In January 2018, a sub-group of the AABB Donor Hemovigilance Working Group undertook the task of developing the
Severity Grading Tool for Donor Adverse Events to enhance objective assignment of Donor Adverse Events (DAE) severity. The severity assignment tool is designed to be used with the
Standard for Surveillance of Complications Related to Blood Donation by ISBT/AABB/IHN.
Please use the
link to provide your feedback.
AABB Donor Hemovigilance Reports
Hemovigilance@aabb.org or +1.301.215.6588.